Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response

Chronic kidney disease (CKD) is an increasing and life‐threatening disease worldwide. Recent evidence indicates that blood coagulation factors promote renal dysfunction in CKD patients. Activated factor X (FXa) inhibitors are safe and first‐line drugs for the prevention of thrombosis in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Lixin, Ohashi, Koji, Ogawa, Hayato, Otaka, Naoya, Kawanishi, Hiroshi, Takikawa, Tomonobu, Ozaki, Yuta, Takahara, Kunihiko, Tatsumi, Minako, Takefuji, Mikito, Murohara, Toyoaki, Ouchi, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905573/
https://www.ncbi.nlm.nih.gov/pubmed/35262272
http://dx.doi.org/10.14814/phy2.15218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905573/
https://www.ncbi.nlm.nih.gov/pubmed/35262272
http://dx.doi.org/10.14814/phy2.15218

Ejemplares similares